(Q37180839)

18 August 2017

1 reference

title

Autoantibodies and neurodegeneration in multiple sclerosis (English)

1 reference

18 August 2017

0 references

1 reference

1 reference

Tamara Vyshkina

1

1 reference

PubMed ID

18521063

18 August 2017

Bernadette Kalman

series ordinal

2

1 reference

18 August 2017

2 June 2008

1 reference

18 August 2017

Laboratory Investigation

1 reference

18 August 2017

88

1 reference

18 August 2017

8

1 reference

18 August 2017

796-807

1 reference

https://scigraph.springernature.com/pub.10.1038/labinvest.2008.53

18 August 2017

0 references

cites work

Control of experimental autoimmune encephalomyelitis by CD4+ suppressor T cells: peripheral versus in situ immunoregulation

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Axonal transection in the lesions of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

MRI relapses have significant pathologic and clinical implications in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

New therapeutic approaches for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

The extracellular matrix in multiple sclerosis lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

B cells: no longer the nondominant arm of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Mitochondria in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Role of mitochondria in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

The involvement of mitochondria in the pathogenesis of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Cryptic axonal antigens and axonal loss in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Neurofascin as a novel target for autoantibody-mediated axonal injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Increased frequencies of serum antibodies to neurofilament light in patients with primary chronic progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Impairment of anterograde and retrograde neurofilament transport after anti-kinesin and anti-dynein antibody microinjection in chicken dorsal root ganglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Retinal antigens are recognized by antibodies present in sera of patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Prevalence of anti-heat shock protein antibodies in cerebrospinal fluids of patients with Guillain-Barré syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Autoantibodies against heterogeneous nuclear ribonucleoprotein B1 in CSF of MS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

The proteasome is a major autoantigen in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Basic and clinical aspects of autoimmune disorders in peripheral nerves

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Serum autoantibodies to cell surface determinants in multiple sclerosis: a flow cytometric study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Disruption of neurofascin localization reveals early changes preceding demyelination and remyelination in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Reduced raft-association of NF155 in active MS-lesions is accompanied by the disruption of the paranodal junction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Cytoplasmic dynein regulates the subcellular distribution of mitochondria by controlling the recruitment of the fission factor dynamin-related protein-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Dynamics of mitochondrial morphology in healthy cells and during apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Rigidity and spasms from autoimmune encephalomyelopathies: stiff-person syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Autoantibodies in type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Anti-heat shock protein 90beta antibodies are detected in patients with multiple sclerosis during remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Humoral autoimmunity as a mediator of CNS repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Biological indicators of the neurodegenerative phase of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

The immunoglobulin G heavy chain repertoire in multiple sclerosis plaques is distinct from the heavy chain repertoire in peripheral blood lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Antigen specificity of clonally expanded and receptor edited cerebrospinal fluid B cells from patients with relapsing remitting MS

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Environmental risk factors for multiple sclerosis. Part I: The role of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Identification of autoantibodies associated with myelin damage in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Pathogenesis of axonal and neuronal damage in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Relationship of immunologic abnormalities and disease stage in multiple sclerosis: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Immunopathogenesis of multiple sclerosis: concepts and controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Biological markers for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Human antiganglioside autoantibodies: validation of ELISA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Axonal transport of neurofilaments in normal and disease states

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Defective neurofilament transport in mouse models of amyotrophic lateral sclerosis: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Enolase and arrestin are novel nonmyelin autoantigens in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Glutamate-mediated glial injury: mechanisms and clinical importance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Excitatory amino acids as a final common pathway for neurologic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Glutamate uptake by oligodendrocytes: Implications for excitotoxicity in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Neurotransmitters in cerebrospinal fluid reflect pathological activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Excitatory amino acids and multiple sclerosis: evidence from cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Glutamate neurotoxicity in cortical cell culture is calcium dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Glutamate receptor expression in multiple sclerosis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

White matter NMDA receptors: an unexpected new therapeutic target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Antibodies against GluR3 peptides are not specific for Rasmussen's encephalitis but are also present in epilepsy patients with severe, early onset disease and intractable seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Absence of antibodies to glutamate receptor type 3 (GluR3) in Rasmussen encephalitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Principles of paraneoplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Proteasome antibodies in paraneoplastic cerebellar degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Diagnostic importance of anti-proteasome antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Vaccinia virus late transcription is activated in vitro by cellular heterogeneous nuclear ribonucleoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Devic's syndrome-like phenotype associated with thymoma and anti-CV2/CRMP5 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Expression of the onconeural CV2/CRMP5 antigen in thymus and thymoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Remyelination-promoting antibodies activate distinct Ca2+ influx pathways in astrocytes and oligodendrocytes: relationship to the mechanism of myelin repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

Prevalence and Clinical Significance of Anti-phospholipid Antibodies in Multiple Sclerosis: a Study of 89 Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

The spectrum of multiple sclerosis: new lessons from pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

7 January 2021

The role of CD4 T cells in the pathogenesis of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

7 January 2021

Neuroimaging in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

7 January 2021

Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

7 January 2021

Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

7 January 2021

Anti-GM1 antibody facilitates leakage in an in vitro blood-nerve barrier model

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

7 January 2021

Passive immunization with anti-ganglioside antibodies directly inhibits axon regeneration in an animal model

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

7 January 2021

Anti-GD2-like IgM autoreactivity in multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

7 January 2021

Antibodies against light neurofilaments in multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

7 January 2021

Immunization with neurofilament light protein induces spastic paresis and axonal degeneration in Biozzi ABH mice

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

7 January 2021

Humoral immunity against glutamic acid decarboxylase and tyrosine phosphatase IA-2 in Lambert-Eaton myasthenic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

7 January 2021

High prevalence of anti-alpha-crystallin antibodies in multiple sclerosis: correlation with severity and activity of disease

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

7 January 2021

Autoantibodies against HSP70 family proteins were detected in the cerebrospinal fluid from patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

7 January 2021

Autoreactive IgG to intracellular proteins in sera of MS patients

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

7 January 2021

Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

7 January 2021

Resistance is futile: antineuronal autoimmunity in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

7 January 2021

Regulation of mitochondrial metabolism by ER Ca2+ release: an intimate connection

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

7 January 2021

A role for complement in phagocytosis of myelin

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

7 January 2021

Critical regulation of CD4+ T cell survival and autoimmunity by beta-arrestin 1

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

7 January 2021

Arresting autoimmunity by blocking beta-arrestin 1

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

7 January 2021

Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

7 January 2021

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

7 January 2021

Immunology of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

7 January 2021

Antibodies to myelin oligodendrocyte glycoprotein as a biomarker in multiple sclerosis--are we there yet?

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

7 January 2021

Heat shock proteins in autoimmune diseases

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

7 January 2021

Altered Glutamate Reuptake in Relapsing-Remitting and Secondary Progressive Multiple Sclerosis Cortex: Correlation With Microglia Infiltration, Demyelination, and Neuronal and Synaptic Damage

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

7 January 2021

Memantine abrogates neurological deficits, but not CNS inflammation, in Lewis rat experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

7 January 2021

Autoimmune encephalomyelitis ameliorated by AMPA antagonists

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

7 January 2021

Multiple sclerosis and glutamate

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

7 January 2021

GluR3 autoantibodies destroy neural cells in a complement-dependent manner modulated by complement regulatory proteins

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

7 January 2021

Formation of complement membrane attack complex in mammalian cerebral cortex evokes seizures and neurodegeneration.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

7 January 2021

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

1 reference

7 January 2021

LEBER'S DISEASE WITH SYMPTOMS RESEMBLING DISSEMINATED SCLEROSIS

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

7 January 2021

Mitochondrial DNA diseases: genotype and phenotype in Leber's hereditary optic neuropathy

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

7 January 2021

Antibodies to human optic nerve in Leber's hereditary optic neuropathy

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

7 January 2021

Antibody-mediated remyelination operates through mechanism independent of immunomodulation

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.53

7 January 2021

10.1038/LABINVEST.2008.53

Identifiers

DOI

1 reference

PubMed ID

18521063

Dimensions Publication ID

18 August 2017

0 references

1 reference

PubMed ID

18521063